GTBP GT Biopharma Inc
Company Analysis
Latest News
🔴 GT Biopharma is trading 6.35% down today after sharp post-split rally
GT Biopharma is trading 6.35% down at $5.60 after a sharp post-split rally. - The 1-for-25 reverse stock split became effective September 8, 2026, reducing...
🟢 GT Biopharma is trading 12.05% up today amid speculative post-split activity
GT Biopharma is trading $6.70 (+12.05%) amid continued speculative post-split activity. • The September 8, 2026, 1-for-25 reverse stock split reduced...
🟢 GT Biopharma is trading 5.52% up in pre-market amid continued post-split volatility
GT Biopharma is trading $6.31 (+5.52%) in pre-market amid continued volatility and speculative trading following its reverse split, though the precise catalyst...
🔴 GT Biopharma is trading 6.19% down in pre-market after a post-reverse-split rally
GT Biopharma is trading 6.19% down at $5.61 after a sharp post-reverse-split rally. • The 1-for-25 reverse stock split became effective September 8, reducing...
🟢 GT Biopharma is trading 10% up today after its 1-for-25 reverse split
GT Biopharma is trading at $5.78, up +10.02% on September 9, 2026, following its 1-for-25 reverse stock split, effective September 8. - Nasdaq began...
🟢 GT Biopharma is trading 8.38% up today following 1-for-25 reverse split effective September 8, 2026
GT Biopharma is trading $5.69 (+8.38%) after its 1-for-25 reverse stock split became effective September 8, 2026. • Nasdaq began split-adjusted trading...
🟢 GT Biopharma is trading 6.48% up in pre-market after its 1-for-25 reverse stock split took effect
GT Biopharma is trading at $5.59 (+6.48%) in pre-market, having rebounded following its 1-for-25 reverse stock split, effective September 8, 2026. - Nasdaq...
🔴 GT Biopharma is trading 10.21% down today after its 1-for-25 reverse stock split took effect
GT Biopharma is trading 10.21% down at $5.41 after its 1-for-25 reverse stock split became effective on September 8, 2026. - Nasdaq confirmed split-adjusted...
🔴 GT Biopharma is trading 6.31% down today after a 1-for-25 reverse stock split became effective
GT Biopharma is trading at $5.64 (-6.31%) on September 8, 2026, after its 1-for-25 reverse stock split became effective. - Nasdaq confirmed the split-adjusted...
🟢 GT Biopharma is trading 7.68% up in after-hours trading after Nasdaq disclosed a 1-for-25 reverse split
GT Biopharma is trading 7.68% up at $0.26 after Nasdaq disclosed a 1-for-25 reverse stock split. - Effective September 8, 2026, the split will consolidate...
🔴 GT Biopharma is trading 12% down today after Nasdaq disclosed 1-for-25 reverse split
GT Biopharma is trading 12% down now at $0.22 after Nasdaq disclosed a 1-for-25 reverse stock split effective September 8, 2026. - The action will consolidate...
🔴 GT Biopharma is trading 7% down today after Nasdaq disclosed 1-for-25 reverse split
GT Biopharma is trading 7.05% down now at $0.23 after Nasdaq disclosed its 1-for-25 reverse stock split, effective September 8, 2026. - The transaction will...
GT Biopharma's 1-for-25 Reverse Split: A Lifeline to Stay Listed or a Warning Sign for Investors?
GT Biopharma's Third Reverse Split in Five Years: Can Financial Engineering Save a Stock That Has Lost 99% of Its Value? Shares of GT Biopharma shifted...
🟢 GT Biopharma is trading 10.90% up in pre-market after Nasdaq disclosed a planned 1-for-25 reverse split
GT Biopharma is trading 10.90% up in pre-market at $0.28 after Nasdaq disclosed a planned 1-for-25 reverse stock split. - The reverse split becomes effective...
🔴 GT Biopharma is trading 10.57% down today with no definitive catalyst identified
GT Biopharma is trading at $0.25, down -10.57%, with no definitive catalyst identified. - No dated company announcement, SEC filing, earnings release, or...
🔴 GT Biopharma is trading 5.65% down today with no clear company-specific catalyst
GT Biopharma is trading at $0.27 (-5.65%) after no clear company-specific catalyst emerged on September 3, 2026. - No dated company announcement, filing,...
🟢 GT Biopharma is trading 7% up in pre-market with no clear company-specific catalyst identified
GT Biopharma is trading 6.96% up at $0.31 in pre-market on September 2, 2026, based on the supplied pre-market data, with no clear company-specific catalyst...
🟢 GT Biopharma is trading 5% up today
GT Biopharma is trading 5% up at $0.32, based on the provided live price; no clear catalyst has been identified. - The latest significant disclosure located...
🟢 GT Biopharma is trading 6.67% up in pre-market; catalyst remains unclear
GT Biopharma is trading 6.67% up at $0.32 in pre-market, with no new company-specific announcement identified for August 31, 2026 and the catalyst unclear. -...
🔴 GT Biopharma is trading 5.17% down in pre-market with no clear company-specific catalyst identified
GT Biopharma is trading at $0.29, down 5.17%, after no clear company-specific catalyst was identified for August 25, 2026. - The latest listed release remains...